Literature DB >> 29959090

Dermal delivery of Fe-chlorophyllin via ultradeformable nanovesicles for photodynamic therapy in melanoma animal model.

Mai Rady1, Iman Gomaa2, Nagia Afifi3, Mahmoud Abdel-Kader4.   

Abstract

Melanoma is resistant to chemotherapeutics with poor prognosis and high potential of metastasis. Photodynamic therapy (PDT) represents a localized therapeutic modality, as cytotoxicity occurs when light activates photosensitizer (PS) at the tumour site. The aim of this study is dermal delivery of a high molecular weight hydrophilic photosensitizer (PS), ferrous chlorophyllin (Fe-CHL) via transethosomes for treatment of melanoma by PDT. Transethosomes were made of phosphatidyl choline, edge activator and 20% w/v Ethanol. They were evaluated for mean size, zeta potential, entrapment efficiency, ex-vivo permeation, localization in skin layers by transmission electron microscope (TEM), and finally, evaluated in melanoma animal model. Transethosomes of different mean vesicle size were evaluated for their skin retention and permeation through mice skin. TE of ∼500 nm (E3) being ultradeformable showed deep localization in skin confirmed by ex-vivo and TEM micrographs without permeation of PS to recipient compartment due to its size. The proposed study offers successful treatment of resistant melanoma by PDT, where complete tumour regression of small tumours occurred after single PDT, while large tumours after double PDT without recurrence for 8 months. This indicates the efficiency of nanovesicles in PS delivery and the efficiency of Fe-CHL in production of reactive oxygen species.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Dermatological melanoma; Fe-chlorophyllin; Photodynamic therapy; Skin delivery; Transethosomes

Mesh:

Substances:

Year:  2018        PMID: 29959090     DOI: 10.1016/j.ijpharm.2018.06.057

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  7 in total

1.  Green Synthesized Honokiol Transfersomes Relieve the Immunosuppressive and Stem-Like Cell Characteristics of the Aggressive B16F10 Melanoma.

Authors:  Yasmeen Ezzeldeen; Shady Swidan; Aliaa ElMeshad; Aya Sebak
Journal:  Int J Nanomedicine       Date:  2021-08-24

Review 2.  Recent Advances in the Structural Design of Photosensitive Agent Formulations Using "Soft" Colloidal Nanocarriers.

Authors:  Agata Pucek; Beata Tokarek; Ewelina Waglewska; Urszula Bazylińska
Journal:  Pharmaceutics       Date:  2020-06-24       Impact factor: 6.321

Review 3.  Phospholipid Vesicles for Dermal/Transdermal and Nasal Administration of Active Molecules: The Effect of Surfactants and Alcohols on the Fluidity of Their Lipid Bilayers and Penetration Enhancement Properties.

Authors:  Hiba Natsheh; Elka Touitou
Journal:  Molecules       Date:  2020-06-27       Impact factor: 4.411

4.  The Topical Nanodelivery of Vismodegib Enhances Its Skin Penetration and Performance In Vitro While Reducing Its Toxicity In Vivo.

Authors:  Maria Natalia Calienni; Daniela Maza Vega; C Facundo Temprana; María Cecilia Izquierdo; David E Ybarra; Ezequiel Bernabeu; Marcela Moretton; Fernando C Alvira; Diego Chiappetta; Silvia Del Valle Alonso; María Jimena Prieto; Jorge Montanari
Journal:  Pharmaceutics       Date:  2021-02-01       Impact factor: 6.321

Review 5.  Self-Assembling Drug Formulations with Tunable Permeability and Biodegradability.

Authors:  Gulnara Gaynanova; Leysan Vasileva; Ruslan Kashapov; Darya Kuznetsova; Rushana Kushnazarova; Anna Tyryshkina; Elmira Vasilieva; Konstantin Petrov; Lucia Zakharova; Oleg Sinyashin
Journal:  Molecules       Date:  2021-11-10       Impact factor: 4.411

6.  Stabilization of Deformable Nanovesicles Based on Insulin-Phospholipid Complex by Freeze-Drying.

Authors:  You Xu; Yiyue Guo; Yuqi Yang; Yingying Meng; Xuejun Xia; Yuling Liu
Journal:  Pharmaceutics       Date:  2019-10-16       Impact factor: 6.321

Review 7.  Topical Administration of Drugs Incorporated in Carriers Containing Phospholipid Soft Vesicles for the Treatment of Skin Medical Conditions.

Authors:  Elka Touitou; Hiba Natsheh
Journal:  Pharmaceutics       Date:  2021-12-10       Impact factor: 6.321

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.